LINC01785

Across TCGA pan-cancer cohorts, LINC01785 RNA differs between tumor and matched normal tissue in 9 of 18 cancer types tested, making tumor–normal expression one of LINC01785’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where LINC01785 RNA is repressed in tumor relative to normal tissue. In most cancer types LINC01785 is over-expressed in tumor, although a few such as THCA and KICH show the opposite, repressed pattern.

THCA, KICH, and LUSC are the cancer types where LINC01785 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in LINC01785 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	Female	II,III,IV	−0.812	<.001	10	view →
KICH	All	All	−0.774	<.001	9	view →
LUSC	Female	All	−0.820	<.001	8	view →
LUAD	Female	II,III,IV	−1.144	<.001	7	view →
KIRC	Male	All	−0.513	<.001	7	view →
COAD	All	II,III,IV	−0.013	.028	5	view →
KIRP	Male	All	−0.494	<.001	4	view →
BRCA	Female	II,III,IV	−0.192	<.001	4	view →
PAAD	Female	All	−0.324	.019	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 9 strongest of 9 lineages.

LINC01785–THCA

Open the THCA breakdown →